ɑ-硫辛酸联合依帕司他治疗2型糖尿病周围神经病变临床疗效评价

摘要

Objective To evaluate the clinical effect of combined therapy ofɑ-lipoic acid and epalrestat for diabetic peripheral neuropathy ( DPN) . Methods 72 patients of type2 diabetic peripheral neuropathy were randomly divided into 3 groups,24 cases in each group,group ofɑ-lipoic acid was only injectedɑ-lipoic acid with 600mg,once daily;group of ep-alrestat was only with 50mg epalrestat orally,three times daily;combination group was injected ɑ-lipoic acid with 600mg, once daily,and taken with 50mg epalrestat orally,three times daily;for three weeks. Toronto clinical scoring system(TCSS), the total symptom score(TSS) and nerve conduction velocity(NCV)were performed before and after therapy. Result The scores of TCSS and TSS were decreased after treatment as compared with before treatment in three groups, and the scores of the combined treatment group were more significantly reduced than that of monotherapy groups;NCV in the com-bined treatment group improved greatly more than that in monotherapy groups;the efficiency was statistically significant( P<0. 05). Conclusion The combined therapy withɑ-lipoic acid and epalrestat has more significant effect than single drug therapy with epalrestat and ɑ-lipoic acid for diabetic peripheral neuropathy in the clinic.%目的：评价ɑ-硫辛酸联合依帕司他治疗2型糖尿病周围神经病变的临床疗效。方法72例2型糖尿病周围神经病变患者,随机分为三组,各24例,ɑ-硫辛酸组使用ɑ-硫辛酸600mg(静滴,1次/天),依帕司他组使用依帕司他50mg(口服,3次/天),联合用药组联合使用ɑ-硫辛酸600mg(静滴,1次/天)及依帕司他50mg(口服,3次/天),疗程3周。治疗前后对各组患者进行多伦多临床评分系统(TCSS)、总症状评分系统(TSS)评分及神经传导速度(NCV)检测。结果治疗3周后三组TCSS、TSS评分较治疗前均降低(P<0.05),联合用药组较单用药组评分降低更明显,组间差异有统计学意义(P<0.05),联合用药组NCV较单用药组明显改善,差异有显著性(P<0.05)。结论ɑ-硫辛酸联合依帕司他治疗糖尿病周围神经病变较单用依帕司他和ɑ-硫辛酸治疗疗效更为显著。